Europe joins Avastin breast cancer review

European regulators are reviewing the benefits of using Roche's (ROG.VX) top-selling Avastin drug in breast cancer, in light of fresh clinical trial results; the review comes as FDA is also reconsidering the indication. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.